Jan Brzezicki

2.0k total citations
12 papers, 909 citations indexed

About

Jan Brzezicki is a scholar working on Pediatrics, Perinatology and Child Health, Immunology and Rheumatology. According to data from OpenAlex, Jan Brzezicki has authored 12 papers receiving a total of 909 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Pediatrics, Perinatology and Child Health, 6 papers in Immunology and 5 papers in Rheumatology. Recurrent topics in Jan Brzezicki's work include Biosimilars and Bioanalytical Methods (6 papers), Pharmaceutical studies and practices (6 papers) and Rheumatoid Arthritis Research and Therapies (4 papers). Jan Brzezicki is often cited by papers focused on Biosimilars and Bioanalytical Methods (6 papers), Pharmaceutical studies and practices (6 papers) and Rheumatoid Arthritis Research and Therapies (4 papers). Jan Brzezicki collaborates with scholars based in Poland, United States and South Korea. Jan Brzezicki's co-authors include Gerd R Burmester, Jiří Vencovský, David Mason, Vibeke Strand, Philip J. Mease, K. Luijtens, Ronald van Vollenhoven, Michael Schiff, Désirée van der Heijde and R. B. M. Landewé and has published in prestigious journals such as SHILAP Revista de lepidopterología, Annals of the Rheumatic Diseases and Journal of the American Academy of Dermatology.

In The Last Decade

Jan Brzezicki

11 papers receiving 869 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jan Brzezicki Poland 8 619 425 252 129 107 12 909
Jocelyn H. Leu United States 17 612 1.0× 553 1.3× 376 1.5× 78 0.6× 59 0.6× 45 1.1k
Heather Jones United States 18 513 0.8× 318 0.7× 159 0.6× 42 0.3× 32 0.3× 54 808
Mykola Stanislavchuk Ukraine 8 358 0.6× 200 0.5× 197 0.8× 107 0.8× 20 0.2× 34 546
Ara Dikranian United States 8 582 0.9× 348 0.8× 305 1.2× 192 1.5× 125 1.2× 18 917
S. Nayiager United States 7 541 0.9× 180 0.4× 245 1.0× 165 1.3× 100 0.9× 10 681
Olav Bjørneboe Norway 11 438 0.7× 105 0.2× 153 0.6× 105 0.8× 48 0.4× 19 674
Naomi B. Klarenbeek Netherlands 16 716 1.2× 161 0.4× 247 1.0× 139 1.1× 69 0.6× 36 885
G. Lukina Russia 11 517 0.8× 187 0.4× 157 0.6× 142 1.1× 115 1.1× 94 633
Yichuan Xia United States 4 156 0.3× 637 1.5× 99 0.4× 16 0.1× 22 0.2× 6 892
R. Rau Germany 11 428 0.7× 111 0.3× 165 0.7× 85 0.7× 66 0.6× 38 623

Countries citing papers authored by Jan Brzezicki

Since Specialization
Citations

This map shows the geographic impact of Jan Brzezicki's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jan Brzezicki with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jan Brzezicki more than expected).

Fields of papers citing papers by Jan Brzezicki

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jan Brzezicki. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jan Brzezicki. The network helps show where Jan Brzezicki may publish in the future.

Co-authorship network of co-authors of Jan Brzezicki

This figure shows the co-authorship network connecting the top 25 collaborators of Jan Brzezicki. A scholar is included among the top collaborators of Jan Brzezicki based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jan Brzezicki. Jan Brzezicki is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

12 of 12 papers shown
1.
Feldman, Steven R., Joanna Narbutt, Giampiero Girolomoni, et al.. (2024). A randomized, double-blind, phase III study assessing clinical similarity of SB17 (proposed ustekinumab biosimilar) to reference ustekinumab in subjects with moderate-to-severe plaque psoriasis. Journal of the American Academy of Dermatology. 91(3). 440–447. 11 indexed citations
2.
Feldman, Steven R., Joanna Narbutt, Giampiero Girolomoni, et al.. (2024). 49140 Clinical similarity of SB17 (Proposed Ustekinumab Biosimilar) to Reference Ustekinumab in Patients with Moderate to Severe Plaque Psoriasis: Randomized, Double-blind, Phase III, 52-Week Results. Journal of the American Academy of Dermatology. 91(3). AB161–AB161. 1 indexed citations
3.
Feldman, Steven R., Joanna Narbutt, Giampiero Girolomoni, et al.. (2024). Biosimilar SB17 versus reference ustekinumab in moderate to severe plaque psoriasis after switching: phase 3 study results up to week 52. Journal of Dermatological Treatment. 35(1). 2436607–2436607. 3 indexed citations
4.
Yoo, Dae‐Hyun, Artur Racewicz, Jan Brzezicki, et al.. (2016). A phase III randomized study to evaluate the efficacy and safety of CT-P13 compared with reference infliximab in patients with active rheumatoid arthritis: 54-week results from the PLANETRA study. Arthritis Research & Therapy. 18(1). 82–82. 137 indexed citations
5.
6.
Fleischmann, Roy, Janet van Adelsberg, Yong Lin, et al.. (2016). Sarilumab and Nonbiologic Disease‐Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis and Inadequate Response or Intolerance to Tumor Necrosis Factor Inhibitors. Arthritis & Rheumatology. 69(2). 277–290. 144 indexed citations
7.
Brzezicki, Jan, et al.. (2015). Unusual location of tuberculosis in the course of tumor necrosis factor α inhibitor therapy. SHILAP Revista de lepidopterología. 53(3). 161–164.
8.
Brzezicki, Jan, et al.. (2015). Atypical course of Henoch-Schonlein purpura in an adult patient. SHILAP Revista de lepidopterología. 53(4). 225–229. 1 indexed citations
9.
10.
Yoo, Dae‐Hyun, Artur Racewicz, Jan Brzezicki, et al.. (2013). OP0068 A Phase 3 Randomised Controlled Trial to Compare CT-P13 with Infliximab in Patients with Active Rheumatoid Arthritis: 54 Week Results from the Planetra Study. Annals of the Rheumatic Diseases. 72. A73–A73. 21 indexed citations
11.
Smolen, Josef S, R. B. M. Landewé, Philip J. Mease, et al.. (2008). Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial. Annals of the Rheumatic Diseases. 68(6). 797–804. 399 indexed citations
12.
Baraf, Herbert S. B., Maria Greenwald, Jan Brzezicki, et al.. (2007). Gastrointestinal side effects of etoricoxib in patients with osteoarthritis: results of the Etoricoxib versus Diclofenac Sodium Gastrointestinal Tolerability and Effectiveness (EDGE) trial.. PubMed. 34(2). 408–20. 67 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jocelyn H. Leu Breakdown of academic impact, for papers by Heather Jones Breakdown of academic impact, for papers by Mykola Stanislavchuk Breakdown of academic impact, for papers by Ara Dikranian Breakdown of academic impact, for papers by S. Nayiager Breakdown of academic impact, for papers by Olav Bjørneboe Breakdown of academic impact, for papers by Naomi B. Klarenbeek Breakdown of academic impact, for papers by G. Lukina Breakdown of academic impact, for papers by Yichuan Xia Breakdown of academic impact, for papers by R. Rau
Rankless by CCL
2026